Aspire Biopharma Holdings, Inc. Files 8-K with Multiple Material Events
Ticker: ASBPW · Form: 8-K · Filed: Feb 21, 2025 · CIK: 1847345
Sentiment: neutral
Topics: definitive-agreement, acquisition, financial-obligation, equity-sale, change-of-control
TL;DR
Aspire Biopharma (formerly PowerUp) dropped an 8-K detailing acquisitions, debt, equity sales, and change of control. Big moves happening.
AI Summary
Aspire Biopharma Holdings, Inc. (formerly PowerUp Acquisition Corp.) filed an 8-K on February 21, 2025, detailing several material events. These include entering into a definitive agreement, completion of an acquisition, creation of financial obligations, unregistered sales of equity, and changes in control. The company, operating in the Pharmaceutical Preparations sector, is located at 1200 Broadway, Floor 3, New York, NY.
Why It Matters
This 8-K filing indicates significant corporate actions and potential shifts in Aspire Biopharma's structure and financial standing, which could impact investors and stakeholders.
Risk Assessment
Risk Level: medium — The filing covers a broad range of significant corporate events including acquisitions, financial obligations, and equity sales, suggesting a period of substantial change and potential volatility.
Key Numbers
- 001-41293 — SEC File Number (Identifies the company's filing history with the SEC.)
- 25652847 — Film Number (A unique identifier for the filing within the SEC's system.)
Key Players & Entities
- Aspire Biopharma Holdings, Inc. (company) — Filer
- PowerUp Acquisition Corp. (company) — Former company name
- 0001493152-25-007898 (document_id) — Accession Number
- 20250221 (date) — Filing date
- 1200 Broadway, Floor 3, New York, NY 10038 (address) — Company business and mail address
FAQ
What specific definitive agreement did Aspire Biopharma Holdings, Inc. enter into?
The filing indicates the entry into a Material Definitive Agreement, but the specific details of the agreement are not provided in this summary.
What was acquired or disposed of in the completion of acquisition or disposition of assets?
The filing notes the completion of an acquisition or disposition of assets, but the specific assets involved are not detailed in this summary.
What are the details of the financial obligations created by Aspire Biopharma?
The 8-K mentions the creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, but the specifics of these obligations are not elaborated here.
What type of equity securities were sold unregistered?
The filing reports unregistered sales of equity securities, but the nature and amount of these securities are not specified in this summary.
What specific changes occurred regarding the company's directors or officers?
The filing lists several items related to directors and officers, including departure, election, appointment, and compensatory arrangements, but the specific individuals and actions are not detailed here.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 21, 2025 regarding Aspire Biopharma Holdings, Inc. (ASBPW).